argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced that it has submitted, and the European Medicines Agency has validated, the marketing authorization application for the Company’s investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis.
August 25, 2021
· 6 min read